ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

ESMO OPEN SCIENCE FOR OPTIMAL CANCER CARE

PODCAST

Immune checkpoint inhibitors alone or in combination for endometrial mismatch repair-deficient/MSI-high population

R. Canario[1,2,3]*, N. Colombo[4,5] & F. Joly[6]

[1]Cancer Metastasis, i3S—Institute for Research & Innovation in Health, Porto; [2]Research Centre, Portuguese Oncology Institute of Porto, Porto; [3]Faculty of Medicine, University of Coimbra, Coimbra, Portugal; [4]Department of Gynecologic Oncology, Istituto Europeo di Oncologia IRCCS, Milan; [5]Department of Medicine and Surgery, Università degli Studi Milano-Bicocca, Milan, Italy; [6]GINECO Group, Department of Medical Oncology, Centre François-Baclesse, University of Caen Normandy, Caen, France

Available online 12 April 2024

Click here to listen to the Podcast

Molecular classification of endometrial cancer has changed the understanding of the distinct pathways underlying this heterogeneous cancer and paved the way to new therapeutic approaches. Mismatch repair-deficient/microsatellite-high (MMRd/MSI-H) tumors comprise up to 30% of the cases. These hypermutated tumors are highly immunogenic and display enhanced programmed death-ligand 1 expression, which reflects on their good responses to immunotherapy. Here, we provide an overview of the best clinical practices in the management of MMRd/MSI-H endometrial cancers, focusing on current evidence for the use of immune checkpoint inhibitors (ICIs). We explored the existing and emerging treatment strategies incorporating ICI in the recurrent/metastatic setting, and discussed factors influencing the choice of currently approved ICI agents and ICI rechallenge. In addition, ongoing clinical trials incorporating ICI in the adjuvant setting, and the potential impact of the distinct biological mechanisms underlying MMRd/MSI-H disease on responses to ICI, were also discussed.

FUNDING

None declared.

DISCLOSURE

RC reports non-financial interest: member of ESMO Communication Committee. NC reports fees for advisory board membership for AstraZeneca, Clovis Oncology, Eisai, GSK, Immunogen, Mersana, MSD/Merck, Nuvation Bio, Oncxerna, Pieris, Roche, Novocure; fees as an invited speaker for AstraZeneca, Clovis Oncology, GSK, MSD/Merck, Eisai institutional research grants from AstraZeneca, Roche, GSK. FJ reports fees for advisory board membership or as an invited speaker from GSK, AstraZeneca, MSD, Janssen, Ipsen, Amgen, Bayer, Astellas, Esai, Seagen, Novocure, Novartis/3A, Esai, and Pfizer. She has received institutional funding from Viatris, GSK, AstraZeneca, BMS, Astellas, and Janssen. She has received travel funds from MSD, GSK, Esai, Ipsen, and Chugai. She is a GCIG member.

*Correspondence to: Dr Rita Canario, Cancer Metastasis, i3S—Institute for Research & Innovation in Health, Porto, Portugal
E-mail: rita.canario@ipatimup.pt (R. Canario).